Merkel Cell Carcinoma (DBCOND0028646)

Identifiers

Synonyms
Merkel Cell Carcinoma (MCC) / Merkel-cell Carcinoma / Merkel Cell Carcinoma (Disorder) / Carcinoma, Merkel Cell / Merkel cell carcinoma / Merkel cell carcinoma, unspecified / Merkel cell carcinoma (morphologic abnormality) / Apudoma of skin (disorder) / Neuroendocrine carcinoma of the skin

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Carboplatin
A alkylating agent used to treat advanced ovarian cancer.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT02890368
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoidestreatment1terminated
NCT04616248
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumorstreatment1recruiting
NCT04977453
GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumorstreatment1 / 2recruiting
NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IONo drug interventionstreatment3recruiting
NCT06056895
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinomatreatment2recruiting
NCT05594290
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgerytreatment2recruiting
NCT04853602
IFx-Hu2.0 Expanded Access ProgramNot AvailableNot Availableavailable
NCT04916002
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancertreatment2active_not_recruiting
NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancerstreatment1 / 2recruiting
NCT02054884
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinomatreatment2terminated
NCT02831179
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumortreatment1withdrawn
NCT02819843
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumorstreatment2completed
NCT06039033
Exploring Merkel Cell Carcinoma Clinical Trial Engagement PatternsNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04393753
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1treatment2completed
NCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignanciestreatment1completed
NCT06008977
Exercise to Boost Response to Checkpoint Blockade ImmunotherapyNo drug interventionsotherNot Availablerecruiting
NCT03370861
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy OutcomesNo drug interventionsNot AvailableNot Availableterminated
NCT02196961
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observationtreatment2active_not_recruiting
NCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignanciestreatment1completed
NCT03935893
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancerstreatment2recruiting
NCT00765193
The Impact of Total Body Skin Examination on Skin Cancer DetectionNo drug interventionsdiagnosticNot Availablecompleted
NCT03783078
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)treatment3completed
NCT03629756
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignanciestreatment1completed
NCT00346385
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumorstreatment1completed
NCT04291885
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinomatreatment2recruiting
NCT04157985
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumorstreatment3recruiting
NCT04869137
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinomatreatment2recruiting
NCT04975152
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinomatreatment1recruiting
NCT03071406
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinomatreatment2active_not_recruiting
NCT06151236
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinomatreatment2recruiting
NCT02514824
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinomatreatment1 / 2completed
NCT01440816
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancertreatment2completed
NCT03210935
French National Database of Rare Dermatological CancersNo drug interventionsNot AvailableNot Availablerecruiting
NCT01526486
Videoscopic Versus Open Inguinal Lymphadenectomy for CancerNo drug interventionstreatmentNot Availablecompleted
NCT06536257
Personalised Immunotherapy PlatformNo drug interventionsNot AvailableNot Availablerecruiting
NCT04160065
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancerstreatment1active_not_recruiting
NCT04116320
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumorstreatment1active_not_recruiting
NCT04874831
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)treatment2withdrawn
NCT04725331
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumorstreatment1 / 2recruiting
NCT03901573
High-Risk Skin Cancers With Atezolizumab Plus NT-I7treatment1 / 2terminated
NCT05076760
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancertreatment1recruiting
NCT05329792
L19IL2/L19TNF in Skin Cancer Patientstreatment2recruiting
NCT05086692
A Beta-only IL-2 ImmunoTherapY Studytreatment1 / 2recruiting
NCT05253144
Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCCNo drug interventionstreatmentNot Availablecompleted
NCT03228667
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitorstreatment2active_not_recruiting
NCT04187872
LITT and Pembrolizumab in Recurrent Brain Metastasistreatment1terminated
NCT00003514
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapytreatment2withdrawn
NCT02643303
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancerstreatment1 / 2completed
NCT03167164
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapytreatment1 / 2withdrawn
NCT03787602
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinomatreatment1 / 2recruiting
NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasistreatment1 / 2recruiting
NCT01013779
Merkel Positron Emission Tomography (PET) Protocoltreatment2completed
NCT04596033
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapytreatment1terminated
NCT04047251
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinomatreatment1recruiting
NCT03988647
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinomatreatment2terminated
NCT02479698
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC VirusNo drug interventionstreatment2recruiting
NCT03583528
DOTATOC PET/CT for Imaging NET PatientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT06448611
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell CarcinomaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05120271
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumorstreatment1 / 2recruiting
NCT06086288
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)treatment2not_yet_recruiting
NCT06223659
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancerstreatment2recruiting
NCT04242199
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNo drug interventionstreatment1active_not_recruiting
NCT05496036
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinomatreatment2recruiting
NCT04349436
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous MalignanciesNo drug interventionstreatment1 / 2recruiting
NCT04234113
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumorstreatment1active_not_recruiting
NCT03458117
T-VEC in Non-melanoma Skin CancerNo drug interventionstreatment1completed
NCT03853317
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapytreatment2terminated
NCT04272034
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNo drug interventionstreatment1active_not_recruiting
NCT03545334
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously StudyNo drug interventionsdiagnosticNot Availablecompleted
NCT03798639
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancertreatment1completed
NCT02978625
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancerstreatment2active_not_recruiting
NCT02035657
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinomatreatment1completed
NCT06021626
A Study of CRD3874-SI in People With Solid TumorsNo drug interventionstreatment1recruiting
NCT00540566
Optical Biopsy of Human Skin in Conjunction With Laser TreatmentNo drug interventionsNot AvailableNot Availablecompleted
NCT05429866
Immunological Variables Associated to ICI Toxicity in Cancer Patientsother2recruiting
NCT05859074
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancertreatment1active_not_recruiting
NCT04792073
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinomatreatment2recruiting
NCT02036476
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinomatreatment2terminated
NCT01913691
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinomatreatment2withdrawn
NCT04705389
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European GuidelinesNo drug interventionsotherNot Availableunknown_status
NCT03435640
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignanciestreatment1 / 2terminated
NCT04106167
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNo drug interventionsNot AvailableNot Availableterminated
NCT03212404
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancerstreatment1recruiting
NCT03841110
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumorstreatment1completed
NCT04590781
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancertreatment1 / 2terminated
NCT05422781
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)No drug interventionstreatment1completed
NCT05100095
Hypofractionated Radiation Therapy for Merkel Cell CarcinomaNo drug interventionstreatment2recruiting
NCT05583708
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancertreatment2suspended
NCT05358938
Exercise to Boost Response to Checkpoint Blockade Immunotherapytreatment0active_not_recruiting
NCT02351128
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analoguestreatment2completed
NCT02471352
Studies of Dermatologic Diseases Biospecimen Acquisition ProtocolNo drug interventionsNot AvailableNot Availablerecruiting
NCT02155647
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)treatment2completed